ArticleCancers2025
Matched-Pair Analysis of Survival in the Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Radiotherapy or Concurrent Chemoradiotherapy Versus Surgical-Based Treatment.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study compared survival outcomes between upfront surgery +/-radiotherapy (RT) and definitive RT with or without chemotherapy (RT/CRT) in HPV-negative oropharyngeal squamous cell carcinoma (OPSCC).
methodsA retrospective matched-pair analysis included 150 patients treated between 1990 and 2020. Fifty (RT/CRT) cases (2009-2020) were matched 2:1 to 100 surgical cases (1990-2009) by sex, subsite, T/N classification, and AJCC 8th stage. Sixty-six percent of surgically treated patients received adjuvant RT. Only HPV-negative tumors confirmed by p16 and HPV DNA testing were analyzed. Survival was assessed with Kaplan-Meier and Cox regression.
resultsRT/CRT achieved significantly higher 5-year overall survival (59% vs. 28%) and disease-specific survival (69% vs. 45%) compared with surgery. Matched-pair analysis showed increased overall mortality (HR 1.91;
conclusionsThese findings indicate that RT/CRT provides superior survival outcomes and better control of distant metastasis and second primary tumors compared with surgery in HPV-negative OPSCC, particularly in stage III disease. RT/CRT should be considered an effective organ-preserving option for this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.